Spero Therapeutics (SPRO) Fundamentals 2026 — P/E 4.8x, Revenue Analysis | SniperIQ

.30 on the NASDAQ. This SniperIQ fundamentals page covers Spero Therapeutics's valuation (P/E 4.8x, P/B 1.4x), profitability (net margin 27.8%), revenue ($60M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Spero Therapeutics's market cap?

Spero Therapeutics (SPRO) has a market capitalization of approximately $76M, trading at

.30 on the NASDAQ. Market cap moves with the live share price.

What is Spero Therapeutics's P/E ratio?

Spero Therapeutics's trailing twelve-month P/E ratio is 4.8x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Spero Therapeutics?

Spero Therapeutics runs a net profit margin of 27.8%, a gross margin of 100.0%, and an operating margin of 24.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Spero Therapeutics generate?

Spero Therapeutics reported revenue of $60M for fiscal year 2025, with net income of $9M and earnings per share (EPS) of 0.15. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Spero Therapeutics pay a dividend?

Spero Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Spero Therapeutics financially healthy?

Spero Therapeutics carries a debt-to-equity ratio of 0.05x and a current ratio of 10.50x, with a market beta of 1.49. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Spero Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Spero Therapeutics (SPRO) the key facts are: market cap $76M, P/E 4.8x, revenue $60M, 52-week range 1.3-3.08. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.